Authors: MOYER TP ENGER RJ CHARLSON JR TEMESGEN Z ESTES L OLIVER LK

Citation: Tp. Moyer et al., METHODS TO MEASURE PROTEASE INHIBITOR (PI) AND REVERSE-TRANSCRIPTASE INHIBITOR (RTI) CONCENTRATIONS IN HUMAN PLASMA, Clinical chemistry, 44, 1998, pp. 386-386

Authors: MOYER TP OLIVER LK

Citation: Tp. Moyer et Lk. Oliver, SUPPORTING PHARMACEUTICAL STUDIES FOR FDA SUBMISSIONS - DIVERSIFYING THE DRUG-MONITORING LABORATORY, Clinical chemistry, 44(2), 1998, pp. 433-436

Authors: FLEMING RA CAPIZZI RL ROSNER GL OLIVER LK SMITH SJ SCHIFFER CA SILVER RT PETERSON BA WEISS RB OMURA GA MAYER RJ VANECHO DA BLOOMFIELD CD SCHILSKY RL

Citation: Ra. Fleming et al., CLINICAL-PHARMACOLOGY OF CYTARABINE IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA - A CANCER AND LEUKEMIA GROUP-B STUDY, Cancer chemotherapy and pharmacology, 36(5), 1995, pp. 425-430

Authors: HOMNICK DN SPILLERS CR COX SR COX JH YELTON LA DELOOF MJ OLIVER LK RINGER TV

Citation: Dn. Homnick et al., SINGLE-DOSE RESPONSE AND MULTIPLE-DOSE-RESPONSE RELATIONSHIPS OF BETA-CAROTENE IN CYSTIC-FIBROSIS, The Journal of pediatrics, 127(3), 1995, pp. 491-494

Authors: EPPS DE KNECHTEL TJ BACZYNSKYJ O DECKER D GUIDO DM BUXSER SE MATHEWS WR BUFFENBARGER SL LUTZKE BS MCCALL JM OLIVER LK KEZDY FJ

Citation: De. Epps et al., TIRILAZAD MESYLATE PROTECTS STORED ERYTHROCYTES AGAINST OSMOTIC FRAGILITY, Chemistry and physics of lipids, 74(2), 1994, pp. 163-174